程序性死亡配体1对转移性肾细胞癌免疫检查点抑制剂治疗的预测价值:系统综述与荟萃分析
该系统综述与荟萃分析纳入6项研究,评估肿瘤PD-L1状态对转移性肾细胞癌(mRCC)患者接受免疫检查点抑制剂(ICI)治疗的预测价值。结果显示,PD-L1阳性患者接受ICI治疗的客观缓解率(ORR)和完全缓解率(CRR)显著更高、疾病进展率(PDR)更低,且无进展生存期(PFS)优于舒尼替尼治疗。PD-L1阳性有助于筛选最可能从ICI治疗中获益的mRCC患者。
要点
- PD-L1阳性mRCC患者接受ICI治疗的ORR、CRR显著更高,PDR更低。
- PD-L1阳性患者ICI治疗PFS优于舒尼替尼,PD-L1阴性者未见此差异。
- 纳武利尤单抗联合伊匹木单抗在PD-L1阳性患者中ORR和PFS最优。
核心结论
- 肿瘤PD-L1阳性与mRCC患者接受ICI治疗时更高的ORR和更长的PFS相关,有助于识别最可能获益的患者。
研究设计与样本
- 系统综述与荟萃分析,检索截至2020年4月的多个数据库,最终纳入6项符合标准的研究。
主要发现
- PD-L1阳性患者接受ICI治疗的ORR显著高于PD-L1阴性患者(OR 1.84,95%CI 1.48-2.28)。
- PD-L1阳性患者接受ICI治疗的CRR显著高于PD-L1阴性患者(OR 3.11,95%CI 2.04-4.75)。
- PD-L1阳性患者接受ICI治疗的PDR显著低于PD-L1阴性患者(OR 0.43,95%CI 0.31-0.60)。
- PD-L1阳性患者接受ICI治疗的PFS显著优于舒尼替尼治疗(HR 0.65,95%CI 0.57-0.74),PD-L1阴性患者中未发现此差异。
- 与舒尼替尼相比,ICI联合治疗在所有被考察的ICI中均显著改善PD-L1阳性患者的ORR和PFS。
关键数值与推荐
- PD-L1阳性患者ICI vs 阴性患者:ORR的OR 1.84(95%CI 1.48-2.28),CRR的OR 3.11(95%CI 2.04-4.75),PDR的OR 0.43(95%CI 0.31-0.60)。
- PD-L1阳性患者ICI vs 舒尼替尼:PFS的HR 0.65(95%CI 0.57-0.74)。
- 纳武利尤单抗联合伊匹木单抗在PD-L1阳性患者中提供最高ORR和最长PFS的可能性最高。
临床怎么用
- 对于mRCC患者,可依据肿瘤PD-L1状态辅助筛选最可能从ICI治疗中获益的人群。
- PD-L1阳性患者优先考虑ICI治疗或ICI联合治疗,PD-L1阴性患者需综合评估其他临床因素。
局限性
- 仅纳入6项研究,样本量有限。
- 检索截止至2020年4月,未涵盖后续新证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Immune-checkpoint inhibitors (ICIs) are a mainstay treatment of metastatic renal cell carcinoma (mRCC). As not all patients benefit from ICIs, a biomarker-driven clinical decision-making strategy is desirable. OBJECTIVE: To assess the predictive value of programmed death ligand 1 (PD-L1) in mRCC patients treated with ICIs. EVIDENCE ACQUISITION: Multiple databases were searched for articles published up to April 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Studies comparing objective response rate (ORR), complete response rate (CRR), progressive disease rate (PDR), or progression-free survival (PFS) based on tumor PD-L1 status in mRCC patients were eligible. EVIDENCE SYNTHESIS: Six studies matched our eligibility criteria. Treatment with ICIs was associated with significantly higher ORRs and CRRs, and lower PDRs in patients with PD-L1-positive tumors than in those with PD-L1-negative status (odds ratio [OR] 1.84, 95% confidence interval [CI] 1.48-2.28; OR 3.11, 95% CI 2.04-4.75; and OR 0.43, 95% CI 0.31-0.60, respectively). ICI treatment was associated with significantly better PFS in PD-L1-positive patients than in sunitinib-treated patients (hazard ratio 0.65, 95% CI 0.57-0.74), whereas this was not found in patients with PD-L1-negative tumors. Compared with sunitinib, ICI combination therapy improved ORRs and PFS significantly in PD-L1-positive patients of all examined ICIs. Nivolumab plus ipilimumab had the highest likelihood of providing the highest ORR and longest PFS in PD-L1-positive patients. CONCLUSIONS: PD-L1 positivity of the tumor is associated with improved ORRs and prolonged PFS in mRCC patients receiving ICI treatment and thus helps identify mRCC patients most likely to benefit from ICI treatment. PATIENT SUMMARY: The use of an immune-checkpoint inhibitor for the treatment of metastatic renal cell carcinoma (mRCC) improved oncological outcomes, and the status of programmed death ligand 1 could contribute to guiding patients and clinicians when determining personalized treatment strategies for mRCC.
引用
- Mori K, Abufaraj M, Mostafaei H, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. 2020. PMID: 33172722. doi:10.1016/j.eururo.2020.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。